CHA University Bundang Medical Center

InstitutionResearch output, impact & collaborations

CHA University Bundang Medical Center is a research organisation in Seongnam-si, KR. OpenAlex records 8,028 works and 337,054 citations for it. 2,133 researchers list it as their most recent affiliation.

8,028

Works

337,054

Citations

2,133

Researchers

63.3

Avg h-index

IDs:ROR OpenAlex

How has CHA University Bundang Medical Center's publication output changed over time?

ScholarIQpublication output · 2014–2020

Output grew0% over the shown period — from 1 works in 2014 to 1 in 2020.

20142015201620172020

What are the most-cited papers on CHA University Bundang Medical Center?

ScholarIQmost cited works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon

The Lancet. 20156,558 Citations

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim, David Planchard, Yuichiro Ohe, Suresh S. Ramalingam, Myung‐Ju Ahn, Sang-We Kim, Wu‐Chou Su, Leora Horn, Daniel Haggstrom, Enriqueta Felip, Joo-Hang Kim, Paul Frewer, Mireille Cantarini, Kathryn H. Brown, Paul A. Dickinson, Serban Ghiorghiu, Malcolm Ranson

New England Journal of Medicine. 20152,126 CitationsOPEN ACCESS

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Göksel, Keunchil Park, Vera Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, C. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, M. Pérol

The Lancet. 20141,312 CitationsOPEN ACCESS

Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

James Chih‐Hsin Yang, Myung‐Ju Ahn, Dong‐Wan Kim, Suresh S. Ramalingam, Lecia V. Sequist, Wu‐Chou Su, Sang-We Kim, Joo-Hang Kim, David Planchard, Enriqueta Felip, Fiona Blackhall, Daniel Haggstrom, Kiyotaka Yoh, Silvia Novello, Kathryn A. Gold, Tomonori Hirashima, Chia‐Chi Lin, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Pasi A. Jänne

Journal of Clinical Oncology. 2017577 CitationsOPEN ACCESS

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement

Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee, Ki Hyeong Lee, Yun‐Gyoo Lee, Young Joo Min, Eun Kyung Cho, Sung Sook Lee, Bong-Seog Kim, Moon Young Choi, Hyo Sup Shim, Jin‐Haeng Chung, Yoon‐La Choi, Min Jeong Lee, Maria Kim, Joo-Hang Kim, Siraj M. Ali, Myung‐Ju Ahn, Byoung Chul Cho

Journal of Clinical Oncology. 2017298 CitationsOPEN ACCESS